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Abstract.
Background: Most frequently encountered diseases affecting the prostate include benign prostatic 
hyperplasia, prostate cancer and prostatitis. Lower urinary tract symptoms (LUTS), including voiding, 
storage, and post-micturition symptoms, are highly prevalent in men with prostate diseases. This study is 
aimed at determing the relationship between prostate volume and lower urinary tract symptoms in African 
men with prostate diseases using the International prostate symptom score as a tool.
Methodology: The study was conducted among 103 men with lower urinary tract symptoms due to 
prostate disease, who presented at the outpatient department of Jos University teaching hospital between 
January 2013 and December 2013. The men were evaluated and categorized according to prostate disease. 
The IPSS of the men were obtained while prostate volume was determined using transabdominal 
ultrasonography.
Results: During the period January 2013 to December 2013 about 103 men were enrolled into the study. 
The mean age of the patients was 62.6yrs (range 21 - 85yrs). Eighty patients (77.7%) had benign prostatic 
hyperplasia, 20 men had Carcinoma of the Prostate (19.4%) while 3 patients had prostatitis. The mean total 
IPSS was 15.3 (range 3 – 34). Seventy-two of the men, representing 69.9% had moderate symptoms while 
the mean prostate volume was 57.8ml (range 20 – 195mls). The Pearson correlation between prostate 
volume and IPSS = 0.13 with a p-value of 0.18. 
Conclusion: This study illustrates that there's no significant relationship between prostate volume and 
International prostate symptom score in African men with prostatic disease.
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INTRODUCTION 
Most frequently encountered diseases affecting the 
prostate include, benign prostatic hyperplasia, 
prostate cancer and prostatitis. Inflammation of 
prostate gland is called Prostatitis, characterized by 
urinary frequency, dysuria, body aches and 
sometimes fever. Prostatitis may be infective and 
non-infective.
Benign Prostatic Hyperplasia or Nodular 
Hyperplasia of the prostate is the non-malignant 
adenomatous overgrowth of prostate gland. It is 
characterized by hyperplasia of prostatic stromal 
and epithelial cells, resulting in the formation of 
large discrete nodules in peri-urethral region of 
prostate.
Prostate cancer is mainly adenomacarcinoma. The 
histology of prostate cancer was 100% 
adenocarcinoma in Lagos. It is the most commonly 
diagnosed cancer among Nigerian men'. The 
hospital incidence was 127/100,000.
Lower urinary tract symptoms (LUTS), including 
voiding, storage, and post-micturition symptoms, 
are highly prevalent in men with prostate diseases.
The AUA-7 symptom index has been adopted by the 
World Health organization (WHO) as the 
International Prostate Symptom Score (IPSS). On 
validation, the AUA-7 index has been shown to have 
excellent test-retest reliability and is internally 
consistent.
The international prostate symptom score (IPSS) is 
widely used to assess the severity of lower urinary 
The exclusion criteria of this study were the use of 
medications affecting prostate growth, such as 5-α-
reductase inhibitors and antiandrogens; use of α1 
inhibitors, the presence of neurogenic bladder 
dysfunction and a previous surgical procedure 
related to prostate disease.
RESULTS 
One hundred and three men were enrolled into the 
study. 
The mean age of the men was 62.6yrs (range 21 – 
85yrs). 
Eighty men (77.7%) had benign prostatic 
hyperplasia; twenty men had adenocarcinoma of the 
prostate (19.4%) while three men had Prostatitis 
(2.9%).
Figure 1: Bar chart showing distribution of 
Prostate diseases.
The mean total IPSS was 15.3 (range 3 – 34). 
Table 1: showing severity of IPSS and there percentages
The mean prostate volume was 57.8ml (range 20ml – 195ml).
Figure 2: Scatter plot of IPSS/ Prostate Volume
The Pearson correlation between prostate volume 
and IPSS is 0.13 (p value 0.18). 
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tract symptoms (LUTS) in men with bladder outlet 
obstruction (BOO) as a result of prostate diseases.
The IPSS consists of seven questions that deal with 
voiding symptoms (incomplete emptying, 
intermittency, weak stream and straining to void) 
and storage symptoms (frequency, urgency and 
nocturia).
Based on symptom index the scores are graded 
according to severity into three subclasses for the 
resulting total score: mild (IPSS 0-7),moderate 
(IPSS 8-19) andsevere (IPSS 20-35) symptoms.
The aim of this study is to establish if there is any 
relationship between prostate volume and 
International Prostate symptom score in African 
men with prostate disease.
MATERIALS AND METHODS
This was a prospective study of men with newly 
diagnosed prostatic disease who presented at the 
outpatient department of Jos University teaching 
hospital between January 2013 and December 
2013
Men with LUTS due to prostate diseases were 
requested to complete the IPSS comprising the 
following questions: Q1 – incomplete emptying, 
Q2 – frequency, Q3 – intermittency, Q4 – urgency, 
Q5 – weak stream, Q6 – straining, Q7 – nocturia, 
(each question is scored 0- 5, maximum total score 
is 35). Study subjects who were unable to complete 
the questionnaires on their own were assisted by a 
doctor.
A full medical history was obtained and physical 
examination, digital rectal examination (DRE), 
urine microscopy, culture and sensitivity and 
prostate-specific antigen (PSA) were assayed.
Men with suspicious prostate and elevated prostate 
specific antigen had prostate biopsy to confirm 
prostate cancer.
Prostate  volume was es t imated using 
t r ansabdomina l  u l t r a sonography.  The  
measurement was done by computing the ellipsoid 
formula which calculates the size by multiplying 
the largest anteroposterior height (H), transverse 
width (W), cephalocaudal length (L) by a constant. 
(H × W × L × п/6).
Pearson correlation (r) was used to evaluate the 
correlation between prostate volume and IPSS.
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DISCUSSION 
Studies using symptom indices and physiologic 
variables to measure relationship of symptom 
severity and prostate volume have been undertaken 
in men with prostate disease''’
Prostate diseases and lower urinary tract symptoms 
are quite prevalent in men with increasing age. In 
this study the mean age of men with prostate disease 
was 62.6years. This is similar to the findings in 
other studies. In Lagos Nigeria the mean age of men 
with prostate disease was 64.4years while in South-
western Nigeria Badmus et al documented similar 
finding.
Common afflictions of the prostate include 
prostatitis, carcinoma of the prostate andbenign 
prostatic hyperplasia. In this study 2.9% (n=3) had 
prostatitis; 19.4% (n=20) had adenocarcinoma of 
the prostate while 77.7% (n=80) had benign 
prostatic hyperplasia.These findings are similar to 
what is recorded in other parts of the world. In 
different studies, the range of prostatitis syndrome 
was 2.2 to 9.7%''.The incidence of prostate cancer 
has surged dramatically in recent years due to 
improved cancer screening and detection 
mechanisms'. Thompson et al recorded a 
prevalence of 15% in the Prostate Cancer 
Prevention Trial. Benign prostatic hyperplasia 
remains the commonest disease affecting the 
prostate. Galic et alin a study of prostate disease 
prevalence recorded high prevalence of benign 
prostate hyperplasia with low prevalence of 
carcinoma of the prostate and prostatitis. 
Overall, 69.9% and 22.3% of the men were 
moderately and severely symptomatic respectively 
using the IPSS to assess symptom severity. This 
shows that most of the men had moderate 
symptoms similar to the findings of McConnell et 
al.
The relationship between prostate volume and IPSS 
has been a controversial issue, however in this 
study there was a weak correlation between 
prostate volume and IPSS. The Pearson correlation 
r= 0.13 with P value of 0.18. This is statistically 
insignificant.Sciarra et al studied the relationship 
among symptom score, urinary flow rate and 
prostate volume in men with lower urinary tract 
symptoms (LUTS). He concluded that symptom 
score weakly correlated with age and prostate 
volume. Bosch et al in a community based study, 
assessing the prevalence and correlation of 
symptoms with age, prostate volume, flow rate and 
residual volume using IPSS as a tool, also showed 
that there was a weak correlation between the IPSS 
and total prostate volume. ® =0.19). 
However,Eckhard et al investigated the associations 
of symptoms and quality of life with age, prostate 
volume, and urodynamic parameters in a large 
group of strictly selected men with lower urinary 
tract symptoms. His conclusion was, except for 
nocturia, older men had higher voiding scores on the 
IPSS. Prostate volume and obstruction grade were 
not associated with high voiding scores on IPSS, but 
low detrusor contractility and low capacities were, 
associated with the symptom index.Rosier et al, in a 
retrospective study involving 521 men with lower 
urinary tract symptoms showed there was no 
correlation between symptom scores ( Madsen and 
IPSS) and prostate size or volume. Barry et al 
showed that at baseline symptom severity was not 
correlated with prostate volume.
Hence, the interpretation of the IPSS values in a 
clinical setting should take the lack of correlation 
and the variability of the parameter values with 
prostate volume into account.
Conclusion: This study illustrates that there's no 
significant relationship between prostate volume 
and International prostate symptom score in African 
men with prostatic disease.
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